Olmesartan/Amlodipine/Hct Eg (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine/Hct Eg is prescribed for hypertension and related cardiovascular risk management pathways.

• Hypertension: helps achieve target blood pressure when single‑agent therapy is insufficient.
• Hypertensive heart disease: reduces cardiac workload and may limit disease progression.
• Chronic kidney disease with hypertension: assists in slowing renal function decline associated with high blood pressure.

• The combination product provides three complementary actions: olmesartan blocks the angiotensin II type‑1 receptor, preventing vasoconstriction and aldosterone release; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide promotes renal sodium and water excretion, decreasing plasma volume. Together they lower systemic vascular resistance and cardiac output, resulting in blood‑pressure reduction.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema
• Flushing
• Fatigue
• Increased urination

Serious or Rare Side Effects

• Severe hypotension
• Electrolyte disturbances (e.g., low potassium)
• Acute kidney injury
• Angio‑edema
• Liver function abnormalities
• Blood cell count changes

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor potassium and sodium levels, especially with diuretic component.
• Hepatic function: use caution in patients with liver disease.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan/Amlodipine/Hct Eg can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine exposure.
• Lithium: may increase lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
• ACE inhibitors or other ARBs: additive blood‑pressure lowering, risk of renal dysfunction.
• Antidiabetic agents: monitor glucose as diuretic may affect glycemic control.